Literature DB >> 24367029

Adoptively transferred immune T cells eradicate established tumors despite cancer-induced immune suppression.

Ainhoa Arina1, Karin Schreiber, David C Binder, Theodore G Karrison, Rebecca B Liu, Hans Schreiber.   

Abstract

Myeloid-derived CD11b(+)Gr1(+) suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) are considered a major obstacle for effective adoptive T cell therapy. Myeloid cells suppress naive T cell proliferation ex vivo and can prevent the generation of T cell responses in vivo. We find, however, that adoptively transferred immune T cells eradicate well-established tumors in the presence of MDSCs and TAMs, which are strongly immunosuppressive ex vivo. These MDSCs and TAMs were comparable in numbers and immunosuppressive capacity among different tumor models. Longitudinal microscopy of tumors in vivo revealed that after T cell transfer, tumor vasculature and cancer cells disappeared simultaneously. During T cell-mediated tumor destruction, the tumor stroma contained abundant myeloid cells (mainly TAMs) that retained their suppressive properties. Preimmunized but not naive mice resisted immune suppression caused by an unrelated tumor burden, supporting the idea that in vivo, myeloid immunosuppressive cells can suppress naive but not memory T cell responses.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24367029      PMCID: PMC4084557          DOI: 10.4049/jimmunol.1202498

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  55 in total

1.  The terminology issue for myeloid-derived suppressor cells.

Authors:  Dmitry I Gabrilovich; Vincenzo Bronte; Shu-Hsia Chen; Mario P Colombo; Augusto Ochoa; Suzanne Ostrand-Rosenberg; Hans Schreiber
Journal:  Cancer Res       Date:  2007-01-01       Impact factor: 12.701

2.  Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics.

Authors:  Naoki Umemura; Masanao Saio; Tatsuhiko Suwa; Yusuke Kitoh; Juncheng Bai; Kenichi Nonaka; Guan-Feng Ouyang; Makoto Okada; Margit Balazs; Roza Adany; Toshiyuki Shibata; Tsuyoshi Takami
Journal:  J Leukoc Biol       Date:  2008-02-19       Impact factor: 4.962

3.  Myeloid-derived suppressor cells are implicated in regulating permissiveness for tumor metastasis during mouse gestation.

Authors:  Laetitia A Mauti; Marie-Aude Le Bitoux; Karine Baumer; Jean-Christophe Stehle; Dela Golshayan; Paolo Provero; Ivan Stamenkovic
Journal:  J Clin Invest       Date:  2011-06-06       Impact factor: 14.808

4.  An eosinophil-dependent mechanism for the antitumor effect of interleukin-4.

Authors:  R I Tepper; R L Coffman; P Leder
Journal:  Science       Date:  1992-07-24       Impact factor: 47.728

5.  High proliferation of granulocyte-macrophage progenitors in tumor-bearing mice.

Authors:  L Balducci; C Hardy
Journal:  Cancer Res       Date:  1983-10       Impact factor: 12.701

6.  GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells.

Authors:  Johanna K Morales; Maciej Kmieciak; Keith L Knutson; Harry D Bear; Masoud H Manjili
Journal:  Breast Cancer Res Treat       Date:  2009-11-08       Impact factor: 4.872

7.  IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers.

Authors:  Bin Zhang; Theodore Karrison; Donald A Rowley; Hans Schreiber
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

8.  Bystander elimination of antigen loss variants in established tumors.

Authors:  Michael T Spiotto; Donald A Rowley; Hans Schreiber
Journal:  Nat Med       Date:  2004-02-22       Impact factor: 53.440

9.  A systematic analysis of experimental immunotherapies on tumors differing in size and duration of growth.

Authors:  Frank T Wen; Ronald A Thisted; Donald A Rowley; Hans Schreiber
Journal:  Oncoimmunology       Date:  2012-03-01       Impact factor: 8.110

10.  Tumor rejection by disturbing tumor stroma cell interactions.

Authors:  S Ibe; Z Qin; T Schüler; S Preiss; T Blankenstein
Journal:  J Exp Med       Date:  2001-12-03       Impact factor: 14.307

View more
  7 in total

Review 1.  Mouse versus Human Neutrophils in Cancer: A Major Knowledge Gap.

Authors:  Evgeniy B Eruslanov; Sunil Singhal; Steven M Albelda
Journal:  Trends Cancer       Date:  2017-01-19

2.  Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1-Resistant Tumors Leading to Tumor Eradication.

Authors:  Ainhoa Arina; Theodore Karrison; Eva Galka; Karin Schreiber; Ralph R Weichselbaum; Hans Schreiber
Journal:  Cancer Immunol Res       Date:  2017-01-11       Impact factor: 11.151

3.  Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3Kδ/γ.

Authors:  Ruth J Davis; Ellen C Moore; Paul E Clavijo; Jay Friedman; Harrison Cash; Zhong Chen; Chris Silvin; Carter Van Waes; Clint Allen
Journal:  Cancer Res       Date:  2017-03-31       Impact factor: 12.701

Review 4.  Vaccines for established cancer: overcoming the challenges posed by immune evasion.

Authors:  Sjoerd H van der Burg; Ramon Arens; Ferry Ossendorp; Thorbald van Hall; Cornelis J M Melief
Journal:  Nat Rev Cancer       Date:  2016-03-11       Impact factor: 60.716

5.  Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation.

Authors:  Matthias Leisegang; Boris Engels; Karin Schreiber; Poh Yin Yew; Kazuma Kiyotani; Christian Idel; Ainhoa Arina; Jaikumar Duraiswamy; Ralph R Weichselbaum; Wolfgang Uckert; Yusuke Nakamura; Hans Schreiber
Journal:  Clin Cancer Res       Date:  2015-12-14       Impact factor: 12.531

6.  Viral infection of implanted meningeal tumors induces antitumor memory T-cells to travel to the brain and eliminate established tumors.

Authors:  Yanhua Gao; Patricia Whitaker-Dowling; Mamdouha A Barmada; Per H Basse; Ira Bergman
Journal:  Neuro Oncol       Date:  2014-09-14       Impact factor: 12.300

7.  Rethinking the role of myeloid-derived suppressor cells in adoptive T-cell therapy for cancer.

Authors:  Ainhoa Arina
Journal:  Oncoimmunology       Date:  2014-04-15       Impact factor: 8.110

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.